Avecho Biotechnology (ASX:AVE) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Avecho Biotechnology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avecho Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$0.08 Mil. Avecho Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was A$0.15 Mil. Avecho Biotechnology's annualized EBITDA for the quarter that ended in Jun. 2026 was A$-6.38 Mil. Avecho Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.04.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Avecho Biotechnology's Debt-to-EBITDA or its related term are showing as below:

ASX:AVE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.37   Med: -0.05   Max: 0.06
Current: -0.03

During the past 13 years, the highest Debt-to-EBITDA Ratio of Avecho Biotechnology was 0.06. The lowest was -0.37. And the median was -0.05.

ASX:AVE's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs ASX:AVE: -0.03

Avecho Biotechnology  (ASX:AVE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Avecho Biotechnology Debt-to-EBITDA Related Terms

Avecho Biotechnology Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Avecho Biotechnology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avecho Biotechnology Debt-to-EBITDA Chart

Avecho Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avecho Biotechnology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ASX:AVE vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Avecho Biotechnology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Debt-to-EBITDA falls into.


Avecho Biotechnology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avecho Biotechnology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.014473 + 0) / -5.814058
=-0.00

Avecho Biotechnology's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.080279 + 0.147266) / -6.377284
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Avecho Biotechnology Business Description

Other Exchanges OEZ:Germany
Address Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.